AstraZeneca Pharma India Limited (BOM:506820)
India · Delayed Price · Currency is INR 8,077.30
-110.85 (-1.35%)
At close: Aug 10, 2026
AstraZeneca Pharma India Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Operating Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 1,875 | 1,157 | 1,615 | 992.9 | 616 |
Depreciation & Amortization | 279.2 | 385.4 | 148.1 | 162.6 | 169.5 |
Other Amortization | 6.6 | 14.5 | 1.3 | - | - |
Loss (Gain) From Sale of Assets | -1.6 | -3.2 | -0.3 | -24.9 | -28.2 |
Asset Writedown & Restructuring Costs | 55.4 | 617.8 | 12.4 | - | - |
Stock-Based Compensation | 10.9 | 51.4 | 27.4 | 23.7 | 18.2 |
Provision & Write-off of Bad Debts | 179.9 | 6.6 | 54.4 | 17 | 42.9 |
Other Operating Activities | -383.2 | -544.1 | -298 | -286.5 | -139.3 |
Change in Accounts Receivable | -458.1 | -316.8 | -511.8 | -231.7 | -49 |
Change in Inventory | -4,788 | -3,206 | -376.7 | -499.9 | 195.8 |
Change in Accounts Payable | 3,264 | 2,598 | -313.7 | 374.4 | 120.5 |
Change in Other Net Operating Assets | -191.4 | -107.3 | -79.5 | 55.3 | 61.6 |
Operating Cash Flow | -151.4 | 653.6 | 278.7 | 582.9 | 1,008 |
Operating Cash Flow Growth | - | 134.52% | -52.19% | -42.17% | -3.80% |
Investing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Capital Expenditures | -15.6 | -17.5 | -107.6 | -85.2 | -96.2 |
Sale of Property, Plant & Equipment | 2.7 | 7.1 | 4.1 | 34.8 | 32.5 |
Other Investing Activities | 199.8 | 318.4 | 320.9 | 231.5 | 111.1 |
Investing Cash Flow | 186.9 | 308 | 217.4 | 181.1 | 47.4 |
Financing Activities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Long-Term Debt Repaid | -74.8 | -41.3 | -38.6 | -38.5 | -35.1 |
Total Debt Repaid | -74.8 | -41.3 | -38.6 | -38.5 | -35.1 |
Net Debt Issued (Repaid) | -74.8 | -41.3 | -38.6 | -38.5 | -35.1 |
Common Dividends Paid | -800 | -600 | -400 | -200 | -50 |
Other Financing Activities | -44.9 | -14.6 | -5.2 | -6.3 | -9.5 |
Financing Cash Flow | -919.7 | -655.9 | -443.8 | -244.8 | -94.6 |
Net Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Cash Flow | -884.2 | 305.7 | 52.3 | 519.2 | 960.8 |
Free Cash Flow
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -167 | 636.1 | 171.1 | 497.7 | 911.8 |
Free Cash Flow Growth | - | 271.77% | -65.62% | -45.42% | -6.07% |
Free Cash Flow Margin | -0.73% | 3.71% | 1.32% | 4.96% | 11.32% |
Free Cash Flow Per Share | -6.68 | 25.44 | 6.84 | 19.91 | 36.47 |
Levered Free Cash Flow | -434.29 | 1,391 | -37.96 | 762.44 | 901.26 |
Unlevered Free Cash Flow | -406.23 | 1,400 | -30.46 | 766.38 | 907.2 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash Interest Paid | 44.9 | 14.6 | 5.2 | 6.3 | 9.5 |
Cash Income Tax Paid | 833.1 | 641.9 | 564.3 | 408.2 | 247.9 |
Change in Working Capital | -2,174 | -1,032 | -1,282 | -301.9 | 328.9 |